IMNN 8-K SEC Filing Analysis

Latest settled — T+5d

IMNN ▼ -16.30% at T+5d

LONG call ✗ call lost -16.30% · α vs SPY -16.37% · entry $2.70 → $2.26

Next anchor: T+20d due 3d ago

Currently $2.02 · -25.19% from $2.70 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

-3.70%

call -3.70% · α -4.28%

$2.60

settled 4w ago

T+5d

-16.30%

call -16.30% · α -16.37%

$2.26

settled 25d ago

T+20d

—

call — · α —

—

due 3d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash burn widened to -$4.0M and cash fell to $4.8M. Clinical progress on IMNN-001's Phase 3 OVATION 3 trial continues, with FDA alignment on the protocol, but the financials highlight a tightening cash runway.

Actionable Insight

The EPS beat is positive but cash depletion and widening operating burn suggest dilution or partnership risk within 2-3 quarters. Watch for secondary offering or licensing deal to extend runway, and for interim OVATION 3 data updates.

Key Facts

Q1 2026 GAAP EPS -$0.84 vs consensus -$0.99 (beat by 15.2%)
Net loss $4.3M vs $4.1M in Q1 2025; operating expenses flat at $4.3M
Cash and equivalents $4.8M at Mar 31, 2026, down from $8.8M at Dec 31, 2025
Operating cash flow -$4.0M vs -$2.8M in prior year quarter
Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on protocol
Strategic reorganization completed Feb 2026 to reduce operating expenses

Financial Impact

EPS beat of $0.15 per share vs consensus, but cash burn accelerated by $1.2M YoY; cash runway ~8 months at current burn

epscashFlowcashPosition

Risk Factors

Cash runway insufficient to complete Phase 3 enrollment without additional financing
No approved products; clinical trial failure would be existential
High stock volatility typical of micro-cap biotech

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-022401
Document: form8-k.htm	0001493152-26-022401
Document: 0001493152-26-022401-index-headers.html	0001493152-26-022401
Document: 0001493152-26-022401-index.html	0001493152-26-022401
Document: 0001493152-26-022401.txt	0001493152-26-022401
8-K Data (Synthetic)	0001493152-26-022401

5 reports for IMNN

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IMNN — sortable, filterable
	Type				Now
Jun 4, 2026 8d ago	8-K BEARISH ★ 6/10	$2.10 $2.06	▲ +1.90%	▼ −0.69%	$2.02 (+3.81%)
May 12, 2026 4w ago	8-K BULLISH ★ 6/10	$2.70 $2.60	▼ −3.70%	▼ −4.28%	$2.02 (−25.19%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 2/10	$2.80 $2.77	▼ −1.07%	▼ −1.87%	$2.02 (−27.86%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$2.94 $2.99	▲ +1.70%	▲ +0.95%	$2.02 (−31.29%)
Mar 24, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$2.94 $2.78	▼ −5.44%	▼ −6.01%	$2.02 (−31.29%)

US Market Status

Market Closed — Opens Mon (49h 38m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access